Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09.
Akebia Therapeutics Inc. (AKBA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 3,266,000 | $5,976,780 | +26% | 0% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,023,275 | $1,872,593 | 0% | |
| 3. | 206,100 | $377,163 | +95% | 0% | |
| 4. | Point72 Asia (Singapore) Steve Cohen | 186,232 | $340,805 | 0.08% | |
| 5. | Balyasny Asset Management Dmitry Balyasny | 178,793 | $327,191 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.43 | 5,800 | 29,731 | 2019-11-20 | Filing | ||
| $3.52 | 15,000 | 28,700 | 2019-11-20 | Filing | ||
| $3.58 | 27,000 | 37,000 | 2019-11-20 | Filing | ||
| $3.44 | 50,000 | 887,732 | 2019-11-20 | Filing | ||
| $3.41 | 50,000 | 63,700 | 2019-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.26 | 12,016 | 651,243 | 2024-05-13 | Filing | ||
| $1.26 | 34,840 | 672,092 | 2024-05-13 | Filing | ||
| $1.15 | 27,000 | 668,840 | 2023-08-25 | Filing | ||
| $1.58 | 8,661 | 706,932 | 2024-02-29 | Filing | ||
| $1.58 | 5,974 | 663,259 | 2024-02-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 16,205,119 | $20,094,348 | 26.73% | |
| 2. | 7,607,472 | $9,433,265 | 0% | |
| 3. | 3,122,824 | $3,872,301 | 0% | |
| 4. | 2,159,364 | $2,677,611 | 0% | |
| 5. | 1,856,925 | $2,302,587 | 0.01% |
News See All
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Akebia Therapeutics' Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call Transcript
Operator: Good day and welcome to Akebia's Second Quarter 2023 Financial Results Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Akebia's First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia's Fourth Quarter 2022 Financial Results Conference Call.
5 Underperforming Stocks Targeted By Short Sellers
In this article we discuss top 5 underperforming stocks targeted by short sellers.
Is AKBA A Good Stock To Buy Now?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Funds Have Never Been This Bullish On Akebia Therapeutics Inc (AKBA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Hedge Funds Are Buying Akebia Therapeutics Inc (AKBA)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Billionaire Hedge Funds
